Development of New Cystic Fibrosis Therapies

Human Lung Cell and Tissue Cores for Evaluation of Pathogenesis and Development of New Therapies for Cystic Fibrosis, Lung Cancer, Asthma and Pulmonary Fibrosis

Protocol Description

This study will examine respiratory tissue that is removed as a result of nasal polypectomy, sinus surgery or lung transplant to identify and characterize cells that may provide an ideal target for new treatments for cystic fibrosis (CF). Similarly, laboratory studies on lung cancer, asthma, pulmonary fibrosis, and other end-stage lung diseases are necessary to better understand these diseases and develop new therapies. About 250 people a year are expected to take part in this study from both Children’s Hospital of Pittsburgh of UPMC and the University of Pittsburgh Medical Center.

Eligibility Criteria

Potential participants include all patients undergoing lung transplantation for any end-stage lung disease, or patients with lung disease undergoing sinus surgery for sinusitis or having nasal polyps removed.
Boys: All ages
Girls: All ages

The only requirement is permission to use tissues that are normally discarded after surgery for further laboratory study.

Status: Open for Enrollment

Source of Support
American Heart Association
American Lung Association
Arthritis Foundation
Cystic Fibrosis Foundation
National Institutes of Health
Scleroderma Foundation

Additional Resources
Cystic Fibrosis

Primary Investigator(s)

Joseph M. Pilewski, MD

Contact Information

To get started, please contact either:
Elizabeth Hortigan,MPH, RN, CCRC
Sandy Hurban, RN
Adrienne Horn, RN

Last Update
December 29, 2013
  • Increase/Decrease Text Size
  • Print This Page
Last Update
December 29, 2013